Several other brokerages also recently weighed in on GBT. Canaccord Genuity Group raised shares of Global Blood Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the company from $40.00 to $72.00 in a research note on Monday, August 8th. Cowen cut Global Blood Therapeutics to a “market perform” rating and increased their target price for the company from $67.00 to $68.50 in a research note on Tuesday, August 9th. William Blair cut Global Blood Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 8th. Wedbush cut Global Blood Therapeutics to a “neutral” rating in a research note on Monday, August 15th. Finally, SVB Leerink lowered Global Blood Therapeutics from an “outperform” rating to a “market perform” rating and set a $68.50 target price on the stock. in a research report on Tuesday, August 9th. Twelve equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Global Blood Therapeutics presently has an average rating of “Hold” and a consensus target price of $65.42.
Global Blood Therapeutics Price Performance
Shares of NASDAQ GBT opened at $68.49 on Monday. Global Blood Therapeutics has a one year low of $21.65 and a one year high of $73.02. The company has a debt-to-equity ratio of 4.92, a quick ratio of 6.17 and a current ratio of 6.88. The company’s fifty day moving average is $68.32 and its two-hundred day moving average is $49.91. The firm has a market capitalization of $4.62 billion, a P/E ratio of -13.67 and a beta of 0.45.
Institutional Investors Weigh In On Global Blood Therapeutics
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.